BP1.15205
Alternative Names: BP115205; TPM-1116Latest Information Update: 31 Oct 2024
Price :
$50 *
At a glance
- Originator Teijin Pharma
- Developer Harmony Biosciences
- Class Sleep disorder therapies
- Mechanism of Action Orexin receptor type 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Narcolepsy
Most Recent Events
- 29 Oct 2024 Pharmacodynamics data from a preclinical trial in Narcolepsy released by Harmony Biosciences
- 30 Apr 2024 Harmony Biosciences plans to file an IND application for Narcolepsy by mid-2025
- 30 Apr 2024 Harmony Biosciences plans to initiate a first-in-human clinical trial for Narcolepsy (PO) in the second half of 2025